FDA officials urged the pharmaceutical industry to notify them early on that there will be missing manufacturing data in new drug applications for breakthrough therapies. Doing so will allow them to make better benefit and risk assessments.
Pharmaceutical manufacturers also cited some of the challenges – as well as the strategies – for meeting tight chemistry, manufacturing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?